Alamar Biosciences shares are trading higher after the company reported better-than-expected Q2 financial results. Also, JP Morgan maintained its Overweight rating on the stock and raised its price target from $32 to $35.
benzinga_article
Alamar Biosciences shares are trading higher after the company reported better-than-expected Q2 financial results. Also, JP Morgan maintained its Overweight rating on the stock and raised its price target from $32 to $35.
